IL297650A - Methods of treating abnormal cell growth - Google Patents

Info

Publication number

IL297650A

IL297650A IL297650A IL29765022A IL297650A IL 297650 A IL297650 A IL 297650A IL 297650 A IL297650 A IL 297650A IL 29765022 A IL29765022 A IL 29765022A IL 297650 A IL297650 A IL 297650A

Authority

IL

Israel

Prior art keywords

cancer

kras

subject

inhibitor

dosed

Prior art date

2020-04-27

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims description 114
• 230000002159 abnormal effect Effects 0.000 title claims description 18
• 230000010261 cell growth Effects 0.000 title claims description 18
• 206010028980 Neoplasm Diseases 0.000 claims description 170
• 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 132
• 229940124647 MEK inhibitor Drugs 0.000 claims description 131
• 201000011510 cancer Diseases 0.000 claims description 109
• 150000003839 salts Chemical class 0.000 claims description 88
• 229940124783 FAK inhibitor Drugs 0.000 claims description 76
• FWLMVFUGMHIOAA-UHFFFAOYSA-N n-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(C(F)(F)F)C(NCC=2C(=NC=CN=2)N(C)S(C)(=O)=O)=N1 FWLMVFUGMHIOAA-UHFFFAOYSA-N 0.000 claims description 54
• LMMJFBMMJUMSJS-UHFFFAOYSA-N CH5126766 Chemical compound CNS(=O)(=O)NC1=NC=CC(CC=2C(OC3=CC(OC=4N=CC=CN=4)=CC=C3C=2C)=O)=C1F LMMJFBMMJUMSJS-UHFFFAOYSA-N 0.000 claims description 51
• 150000001875 compounds Chemical class 0.000 claims description 49
• 229950008937 defactinib Drugs 0.000 claims description 49
• 230000035772 mutation Effects 0.000 claims description 49
• 238000011282 treatment Methods 0.000 claims description 46
• 102200006531 rs121913529 Human genes 0.000 claims description 43
• 239000003795 chemical substances by application Substances 0.000 claims description 34
• 230000009977 dual effect Effects 0.000 claims description 27
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 26
• 102200006539 rs121913529 Human genes 0.000 claims description 25
• 102100030708 GTPase KRas Human genes 0.000 claims description 21
• 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims description 21
• 239000000203 mixture Substances 0.000 claims description 21
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 21
• 239000003112 inhibitor Substances 0.000 claims description 19
• 101150105104 Kras gene Proteins 0.000 claims description 18
• 102200006537 rs121913529 Human genes 0.000 claims description 15
• 102200006538 rs121913530 Human genes 0.000 claims description 15
• 206010069755 K-ras gene mutation Diseases 0.000 claims description 14
• 102200006540 rs121913530 Human genes 0.000 claims description 14
• 102200006541 rs121913530 Human genes 0.000 claims description 14
• 229940126685 KRAS G12R Drugs 0.000 claims description 12
• 230000001225 therapeutic effect Effects 0.000 claims description 10
• 206010064571 Gene mutation Diseases 0.000 claims description 8
• 238000003556 assay Methods 0.000 claims description 8
• ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 claims description 8
• 239000000523 sample Substances 0.000 claims description 7
• 108020004705 Codon Proteins 0.000 claims description 6
• 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims description 6
• 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims description 6
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
• 208000009956 adenocarcinoma Diseases 0.000 claims description 6
• 229960002271 cobimetinib Drugs 0.000 claims description 6
• RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 claims description 6
• GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 claims description 5
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 5
• 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 5
• 206010033128 Ovarian cancer Diseases 0.000 claims description 5
• 206010039491 Sarcoma Diseases 0.000 claims description 5
• 230000008901 benefit Effects 0.000 claims description 5
• 201000003914 endometrial carcinoma Diseases 0.000 claims description 5
• 201000005249 lung adenocarcinoma Diseases 0.000 claims description 5
• 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 5
• CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 claims description 5
• 229960004066 trametinib Drugs 0.000 claims description 5
• LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims description 5
• RWEVIPRMPFNTLO-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1F RWEVIPRMPFNTLO-UHFFFAOYSA-N 0.000 claims description 4
• IGUBBWJDMLCRIK-UHFFFAOYSA-N 2-[[2-(2-methoxy-4-morpholin-4-ylanilino)-5-(trifluoromethyl)pyridin-4-yl]amino]-n-methylbenzamide Chemical group CNC(=O)C1=CC=CC=C1NC1=CC(NC=2C(=CC(=CC=2)N2CCOCC2)OC)=NC=C1C(F)(F)F IGUBBWJDMLCRIK-UHFFFAOYSA-N 0.000 claims description 4
• BVAHPPKGOOJSPU-UHFFFAOYSA-N 2-[[5-chloro-2-[(5-methyl-2-propan-2-ylpyrazol-3-yl)amino]pyridin-4-yl]amino]-n-methoxybenzamide Chemical group CONC(=O)C1=CC=CC=C1NC1=CC(NC=2N(N=C(C)C=2)C(C)C)=NC=C1Cl BVAHPPKGOOJSPU-UHFFFAOYSA-N 0.000 claims description 4
• UYJNQQDJUOUFQJ-UHFFFAOYSA-N 2-[[5-chloro-2-[2-methoxy-4-(4-morpholinyl)anilino]-4-pyrimidinyl]amino]-N-methylbenzamide Chemical group CNC(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(=CC=2)N2CCOCC2)OC)=NC=C1Cl UYJNQQDJUOUFQJ-UHFFFAOYSA-N 0.000 claims description 4
• HLFGQICCFZTXTP-UHFFFAOYSA-N 2-chloro-n-(12-cyanoindolizino[2,3-b]quinoxalin-2-yl)benzamide Chemical compound ClC1=CC=CC=C1C(=O)NC1=CC2=C(C#N)C3=NC4=CC=CC=C4N=C3N2C=C1 HLFGQICCFZTXTP-UHFFFAOYSA-N 0.000 claims description 4
• ULMMVBPTWVRPSI-UHFFFAOYSA-N 2-fluoro-5-methoxy-4-[[4-[(2-methyl-3-oxo-1h-isoindol-4-yl)oxy]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-n-(1-methylpiperidin-4-yl)benzamide Chemical group FC=1C=C(NC=2N=C(OC=3C=4C(=O)N(C)CC=4C=CC=3)C(=CN=2)C(F)(F)F)C(OC)=CC=1C(=O)NC1CCN(C)CC1 ULMMVBPTWVRPSI-UHFFFAOYSA-N 0.000 claims description 4
• RCLQNICOARASSR-SECBINFHSA-N 3-[(2r)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione Chemical compound FC=1C(=O)N(C)C=2N=CN(C[C@@H](O)CO)C(=O)C=2C=1NC1=CC=C(I)C=C1F RCLQNICOARASSR-SECBINFHSA-N 0.000 claims description 4
• YWPHBSHEGTZPNS-UHFFFAOYSA-N ClC=1C(=NC(=NC=1)NC1=C(C=C(C(=C1)C)C=1CCN(CC=1)C1CCOCC1)OC(C)C)NC1=C(C=CC=C1)S(=O)(=O)C(C)C Chemical group ClC=1C(=NC(=NC=1)NC1=C(C=C(C(=C1)C)C=1CCN(CC=1)C1CCOCC1)OC(C)C)NC1=C(C=CC=C1)S(=O)(=O)C(C)C YWPHBSHEGTZPNS-UHFFFAOYSA-N 0.000 claims description 4
• 208000005431 Endometrioid Carcinoma Diseases 0.000 claims description 4
• RFWVETIZUQEJEF-UHFFFAOYSA-N GDC-0623 Chemical compound OCCONC(=O)C=1C=CC2=CN=CN2C=1NC1=CC=C(I)C=C1F RFWVETIZUQEJEF-UHFFFAOYSA-N 0.000 claims description 4
• VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 claims description 4
• SUDAHWBOROXANE-SECBINFHSA-N PD 0325901 Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-SECBINFHSA-N 0.000 claims description 4
• 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
• 229950003054 binimetinib Drugs 0.000 claims description 4
• 239000012472 biological sample Substances 0.000 claims description 4
• RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 claims description 4
• 208000028730 endometrioid adenocarcinoma Diseases 0.000 claims description 4
• RYYNGWLOYLRZLK-RBUKOAKNSA-N pf03814735 Chemical group C1([C@H]2CC[C@@H](C1=CC=1)N2C(=O)CNC(=O)C)=CC=1NC(N=1)=NC=C(C(F)(F)F)C=1NC1CCC1 RYYNGWLOYLRZLK-RBUKOAKNSA-N 0.000 claims description 4
• 229950002592 pimasertib Drugs 0.000 claims description 4
• 230000008569 process Effects 0.000 claims description 4
• 229950008933 refametinib Drugs 0.000 claims description 4
• 229950010746 selumetinib Drugs 0.000 claims description 4
• QUSSZSMDFABHLI-UHFFFAOYSA-N 3-methoxy-n-(1-methylpiperidin-4-yl)-4-[[4-[(3-oxo-1,2-dihydroinden-4-yl)oxy]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide Chemical group C=1C=C(NC=2N=C(OC=3C=4C(=O)CCC=4C=CC=3)C(=CN=2)C(F)(F)F)C(OC)=CC=1C(=O)NC1CCN(C)CC1 QUSSZSMDFABHLI-UHFFFAOYSA-N 0.000 claims description 3
• 206010009944 Colon cancer Diseases 0.000 claims description 3
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
• 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims description 3
• 241000124008 Mammalia Species 0.000 claims description 3
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 3
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 3
• 238000006467 substitution reaction Methods 0.000 claims description 3
• 201000002510 thyroid cancer Diseases 0.000 claims description 3
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
• 230000004663 cell proliferation Effects 0.000 claims description 2
• 230000001413 cellular effect Effects 0.000 claims description 2
• 208000037765 diseases and disorders Diseases 0.000 claims description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
• 201000002528 pancreatic cancer Diseases 0.000 claims description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
• 102200006532 rs112445441 Human genes 0.000 claims description 2
• 235000002639 sodium chloride Nutrition 0.000 claims 60
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 59
• 238000002560 therapeutic procedure Methods 0.000 claims 33
• 201000010099 disease Diseases 0.000 claims 31
• 210000004027 cell Anatomy 0.000 claims 28
• 208000035475 disorder Diseases 0.000 claims 28
• 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 claims 21
• -1 digluconate Chemical compound 0.000 claims 20
• 239000003814 drug Substances 0.000 claims 20
• 239000008194 pharmaceutical composition Substances 0.000 claims 15
• 229940079593 drug Drugs 0.000 claims 14
• 206010061289 metastatic neoplasm Diseases 0.000 claims 11
• 230000001394 metastastic effect Effects 0.000 claims 9
• 208000024891 symptom Diseases 0.000 claims 9
• 210000001519 tissue Anatomy 0.000 claims 9
• 206010006187 Breast cancer Diseases 0.000 claims 8
• 208000026310 Breast neoplasm Diseases 0.000 claims 8
• 230000000694 effects Effects 0.000 claims 8
• 210000004072 lung Anatomy 0.000 claims 8
• 230000002611 ovarian Effects 0.000 claims 8
• 238000002626 targeted therapy Methods 0.000 claims 8
• 238000002648 combination therapy Methods 0.000 claims 7
• 239000003937 drug carrier Substances 0.000 claims 7
• 239000006186 oral dosage form Substances 0.000 claims 7
• 230000004044 response Effects 0.000 claims 7
• 238000001356 surgical procedure Methods 0.000 claims 7
• 239000003826 tablet Substances 0.000 claims 7
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 6
• 238000001574 biopsy Methods 0.000 claims 6
• 210000000481 breast Anatomy 0.000 claims 6
• 238000002512 chemotherapy Methods 0.000 claims 6
• 238000009169 immunotherapy Methods 0.000 claims 6
• 230000003211 malignant effect Effects 0.000 claims 6
• 230000001613 neoplastic effect Effects 0.000 claims 6
• 239000002245 particle Substances 0.000 claims 6
• 239000000546 pharmaceutical excipient Substances 0.000 claims 6
• 230000002062 proliferating effect Effects 0.000 claims 6
• 239000004480 active ingredient Substances 0.000 claims 5
• 239000000047 product Substances 0.000 claims 5
• 108090000623 proteins and genes Proteins 0.000 claims 5
• 201000009030 Carcinoma Diseases 0.000 claims 4
• PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 claims 4
• 206010025323 Lymphomas Diseases 0.000 claims 4
• 206010027406 Mesothelioma Diseases 0.000 claims 4
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 4
• 230000001594 aberrant effect Effects 0.000 claims 4
• 210000001072 colon Anatomy 0.000 claims 4
• 239000002552 dosage form Substances 0.000 claims 4
• 230000002357 endometrial effect Effects 0.000 claims 4
• 230000012010 growth Effects 0.000 claims 4
• 238000001794 hormone therapy Methods 0.000 claims 4
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 4
• 230000000977 initiatory effect Effects 0.000 claims 4
• 210000004185 liver Anatomy 0.000 claims 4
• WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 claims 4
• 238000009097 single-agent therapy Methods 0.000 claims 4
• 239000000243 solution Substances 0.000 claims 4
• 229940124597 therapeutic agent Drugs 0.000 claims 4
• NFLLKCVHYJRNRH-UHFFFAOYSA-N 8-chloro-1,3-dimethyl-7H-purine-2,6-dione 2-(diphenylmethyl)oxy-N,N-dimethylethanamine Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Cl)=N2.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 NFLLKCVHYJRNRH-UHFFFAOYSA-N 0.000 claims 3
• 108020004414 DNA Proteins 0.000 claims 3
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 3
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 3
• 208000002250 Hematologic Neoplasms Diseases 0.000 claims 3
• 241000282412 Homo Species 0.000 claims 3
• OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 claims 3
• 229910019142 PO4 Inorganic materials 0.000 claims 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 3
• 208000006265 Renal cell carcinoma Diseases 0.000 claims 3
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 3
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 3
• 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 3
• 239000002253 acid Substances 0.000 claims 3
• 230000004913 activation Effects 0.000 claims 3
• 238000011374 additional therapy Methods 0.000 claims 3
• 239000000654 additive Substances 0.000 claims 3
• 230000000996 additive effect Effects 0.000 claims 3
• 239000002671 adjuvant Substances 0.000 claims 3
• 229940121363 anti-inflammatory agent Drugs 0.000 claims 3
• 239000002260 anti-inflammatory agent Substances 0.000 claims 3
• 239000002111 antiemetic agent Substances 0.000 claims 3
• 229940125683 antiemetic agent Drugs 0.000 claims 3
• 239000002585 base Substances 0.000 claims 3
• 210000004369 blood Anatomy 0.000 claims 3
• 239000008280 blood Substances 0.000 claims 3
• 210000004556 brain Anatomy 0.000 claims 3
• 239000002775 capsule Substances 0.000 claims 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
• 229940111134 coxibs Drugs 0.000 claims 3
• 208000030381 cutaneous melanoma Diseases 0.000 claims 3
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 3
• 229940127089 cytotoxic agent Drugs 0.000 claims 3
• 238000009472 formulation Methods 0.000 claims 3
• 229940088597 hormone Drugs 0.000 claims 3
• 239000005556 hormone Substances 0.000 claims 3
• 208000032839 leukemia Diseases 0.000 claims 3
• 239000007788 liquid Substances 0.000 claims 3
• 208000020816 lung neoplasm Diseases 0.000 claims 3
• 201000001441 melanoma Diseases 0.000 claims 3
• 231100000252 nontoxic Toxicity 0.000 claims 3
• 230000003000 nontoxic effect Effects 0.000 claims 3
• 230000000144 pharmacologic effect Effects 0.000 claims 3
• 235000021317 phosphate Nutrition 0.000 claims 3
• 238000003752 polymerase chain reaction Methods 0.000 claims 3
• 239000000843 powder Substances 0.000 claims 3
• 230000002265 prevention Effects 0.000 claims 3
• WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 claims 3
• 230000000069 prophylactic effect Effects 0.000 claims 3
• 210000002307 prostate Anatomy 0.000 claims 3
• 235000018102 proteins Nutrition 0.000 claims 3
• 102000004169 proteins and genes Human genes 0.000 claims 3
• 230000005855 radiation Effects 0.000 claims 3
• 238000001959 radiotherapy Methods 0.000 claims 3
• 238000012163 sequencing technique Methods 0.000 claims 3
• 210000003491 skin Anatomy 0.000 claims 3
• 210000000813 small intestine Anatomy 0.000 claims 3
• 210000002784 stomach Anatomy 0.000 claims 3
• 239000000126 substance Substances 0.000 claims 3
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 3
• 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
• RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims 2
• MFWNKCLOYSRHCJ-AGUYFDCRSA-N 1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]-3-indazolecarboxamide Chemical compound C1=CC=C2C(C(=O)NC3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-AGUYFDCRSA-N 0.000 claims 2
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 2
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 2
• 208000030808 Clear cell renal carcinoma Diseases 0.000 claims 2
• 108010092160 Dactinomycin Proteins 0.000 claims 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 2
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
• 239000004471 Glycine Substances 0.000 claims 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 2
• 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
• 102000043136 MAP kinase family Human genes 0.000 claims 2
• 108091054455 MAP kinase family Proteins 0.000 claims 2
• SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims 2
• ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims 2
• 241001465754 Metazoa Species 0.000 claims 2
• 208000034578 Multiple myelomas Diseases 0.000 claims 2
• 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
• 208000014767 Myeloproliferative disease Diseases 0.000 claims 2
• 229910002651 NO3 Inorganic materials 0.000 claims 2
• BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims 2
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 2
• 206010029260 Neuroblastoma Diseases 0.000 claims 2
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
• 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
• 239000002202 Polyethylene glycol Substances 0.000 claims 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
• 206010038111 Recurrent cancer Diseases 0.000 claims 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 2
• 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
• 201000005969 Uveal melanoma Diseases 0.000 claims 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 2
• 230000009471 action Effects 0.000 claims 2
• 229910052784 alkaline earth metal Inorganic materials 0.000 claims 2
• 150000008052 alkyl sulfonates Chemical class 0.000 claims 2
• 150000001413 amino acids Chemical class 0.000 claims 2
• 239000000730 antalgic agent Substances 0.000 claims 2
• 229940111136 antiinflammatory and antirheumatic drug fenamates Drugs 0.000 claims 2
• 229940126313 avutometinib Drugs 0.000 claims 2
• 210000003719 b-lymphocyte Anatomy 0.000 claims 2
• 239000011230 binding agent Substances 0.000 claims 2
• 230000000903 blocking effect Effects 0.000 claims 2
• 239000000969 carrier Substances 0.000 claims 2
• 230000032823 cell division Effects 0.000 claims 2
• 210000003169 central nervous system Anatomy 0.000 claims 2
• 239000012829 chemotherapy agent Substances 0.000 claims 2
• 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims 2
• 238000011260 co-administration Methods 0.000 claims 2
• BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 claims 2
• OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 2
• 238000009096 combination chemotherapy Methods 0.000 claims 2
• 239000007891 compressed tablet Substances 0.000 claims 2
• 239000002254 cytotoxic agent Substances 0.000 claims 2
• 231100000599 cytotoxic agent Toxicity 0.000 claims 2
• 229960000975 daunorubicin Drugs 0.000 claims 2
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 2
• 230000001419 dependent effect Effects 0.000 claims 2
• 229960003957 dexamethasone Drugs 0.000 claims 2
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
• 229960001259 diclofenac Drugs 0.000 claims 2
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 2
• 229960000616 diflunisal Drugs 0.000 claims 2
• HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims 2
• 239000003085 diluting agent Substances 0.000 claims 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
• ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 2
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims 2
• 229940043264 dodecyl sulfate Drugs 0.000 claims 2
• 229960004679 doxorubicin Drugs 0.000 claims 2
• 229960001850 droxicam Drugs 0.000 claims 2
• OEHFRZLKGRKFAS-UHFFFAOYSA-N droxicam Chemical compound C12=CC=CC=C2S(=O)(=O)N(C)C(C2=O)=C1OC(=O)N2C1=CC=CC=N1 OEHFRZLKGRKFAS-UHFFFAOYSA-N 0.000 claims 2
• 210000003238 esophagus Anatomy 0.000 claims 2
• 229960005293 etodolac Drugs 0.000 claims 2
• XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims 2
• 239000000284 extract Substances 0.000 claims 2
• ZWJINEZUASEZBH-UHFFFAOYSA-N fenamic acid Chemical class OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 claims 2
• 229960001419 fenoprofen Drugs 0.000 claims 2
• 229960004369 flufenamic acid Drugs 0.000 claims 2
• LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 claims 2
• 229960002390 flurbiprofen Drugs 0.000 claims 2
• SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims 2
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
• 230000037406 food intake Effects 0.000 claims 2
• 201000006585 gastric adenocarcinoma Diseases 0.000 claims 2
• 230000002496 gastric effect Effects 0.000 claims 2
• 239000000499 gel Substances 0.000 claims 2
• 239000008187 granular material Substances 0.000 claims 2
• LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims 2
• 208000014829 head and neck neoplasm Diseases 0.000 claims 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
• 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
• OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 2
• 229960001680 ibuprofen Drugs 0.000 claims 2
• 230000028993 immune response Effects 0.000 claims 2
• 229960000905 indomethacin Drugs 0.000 claims 2
• 239000004615 ingredient Substances 0.000 claims 2
• 210000000936 intestine Anatomy 0.000 claims 2
• YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 claims 2
• 229950002252 isoxicam Drugs 0.000 claims 2
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 2
• 229960000991 ketoprofen Drugs 0.000 claims 2
• 229960004752 ketorolac Drugs 0.000 claims 2
• OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims 2
• 210000003734 kidney Anatomy 0.000 claims 2
• 229960002373 loxoprofen Drugs 0.000 claims 2
• BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 claims 2
• 201000005202 lung cancer Diseases 0.000 claims 2
• 210000001165 lymph node Anatomy 0.000 claims 2
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 2
• 230000036210 malignancy Effects 0.000 claims 2
• 208000006178 malignant mesothelioma Diseases 0.000 claims 2
• 201000005282 malignant pleural mesothelioma Diseases 0.000 claims 2
• 239000000463 material Substances 0.000 claims 2
• 229960003803 meclofenamic acid Drugs 0.000 claims 2
• 229960003464 mefenamic acid Drugs 0.000 claims 2
• HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims 2
• 229960001929 meloxicam Drugs 0.000 claims 2
• 239000012528 membrane Substances 0.000 claims 2
• 206010027191 meningioma Diseases 0.000 claims 2
• TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims 2
• 150000007522 mineralic acids Chemical class 0.000 claims 2
• RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims 2
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
• 210000000214 mouth Anatomy 0.000 claims 2
• 229960004270 nabumetone Drugs 0.000 claims 2
• 229960002009 naproxen Drugs 0.000 claims 2
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 2
• 210000000441 neoplastic stem cell Anatomy 0.000 claims 2
• 229960000965 nimesulide Drugs 0.000 claims 2
• HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 claims 2
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
• 102000039446 nucleic acids Human genes 0.000 claims 2
• 108020004707 nucleic acids Proteins 0.000 claims 2
• 150000007523 nucleic acids Chemical class 0.000 claims 2
• 150000007524 organic acids Chemical class 0.000 claims 2
• 235000005985 organic acids Nutrition 0.000 claims 2
• 210000001672 ovary Anatomy 0.000 claims 2
• 229960002739 oxaprozin Drugs 0.000 claims 2
• OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 claims 2
• CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 claims 2
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims 2
• 210000003800 pharynx Anatomy 0.000 claims 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
• 239000010452 phosphate Substances 0.000 claims 2
• 239000006187 pill Substances 0.000 claims 2
• 229960002702 piroxicam Drugs 0.000 claims 2
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 2
• 210000002381 plasma Anatomy 0.000 claims 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
• 229920001223 polyethylene glycol Polymers 0.000 claims 2
• 229910052700 potassium Inorganic materials 0.000 claims 2
• 239000011591 potassium Substances 0.000 claims 2
• 238000002360 preparation method Methods 0.000 claims 2
• 102000004196 processed proteins & peptides Human genes 0.000 claims 2
• 108090000765 processed proteins & peptides Proteins 0.000 claims 2
• 238000012545 processing Methods 0.000 claims 2
• 229960003111 prochlorperazine Drugs 0.000 claims 2
• DSKIOWHQLUWFLG-SPIKMXEPSA-N prochlorperazine maleate Chemical compound [H+].[H+].[H+].[H+].[O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 DSKIOWHQLUWFLG-SPIKMXEPSA-N 0.000 claims 2
• 229960003910 promethazine Drugs 0.000 claims 2
• 238000011321 prophylaxis Methods 0.000 claims 2
• 239000002464 receptor antagonist Substances 0.000 claims 2
• 229940044551 receptor antagonist Drugs 0.000 claims 2
• 102000027426 receptor tyrosine kinases Human genes 0.000 claims 2
• 108091008598 receptor tyrosine kinases Proteins 0.000 claims 2
• 230000009467 reduction Effects 0.000 claims 2
• 150000003902 salicylic acid esters Chemical class 0.000 claims 2
• 229960000953 salsalate Drugs 0.000 claims 2
• 238000012216 screening Methods 0.000 claims 2
• 229930000044 secondary metabolite Natural products 0.000 claims 2
• 210000002966 serum Anatomy 0.000 claims 2
• 201000003708 skin melanoma Diseases 0.000 claims 2
• 150000003384 small molecules Chemical class 0.000 claims 2
• 239000011780 sodium chloride Substances 0.000 claims 2
• 210000000130 stem cell Anatomy 0.000 claims 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
• 229960000894 sulindac Drugs 0.000 claims 2
• MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 2
• 230000004083 survival effect Effects 0.000 claims 2
• 239000000725 suspension Substances 0.000 claims 2
• 239000006188 syrup Substances 0.000 claims 2
• 235000020357 syrup Nutrition 0.000 claims 2
• 229960002871 tenoxicam Drugs 0.000 claims 2
• WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 claims 2
• 210000001550 testis Anatomy 0.000 claims 2
• 210000001685 thyroid gland Anatomy 0.000 claims 2
• 229960002905 tolfenamic acid Drugs 0.000 claims 2
• YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 claims 2
• 210000002105 tongue Anatomy 0.000 claims 2
• 229960005267 tositumomab Drugs 0.000 claims 2
• 229960000575 trastuzumab Drugs 0.000 claims 2
• 229960003688 tropisetron Drugs 0.000 claims 2
• ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 claims 2
• 210000003932 urinary bladder Anatomy 0.000 claims 2
• 210000002700 urine Anatomy 0.000 claims 2
• 206010046766 uterine cancer Diseases 0.000 claims 2
• 235000013311 vegetables Nutrition 0.000 claims 2
• 239000003981 vehicle Substances 0.000 claims 2
• LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 claims 1
• NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 claims 1
• DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims 1
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims 1
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 1
• TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 1
• HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 claims 1
• VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
• CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims 1
• QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 claims 1
• 229940080296 2-naphthalenesulfonate Drugs 0.000 claims 1
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims 1
• QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 claims 1
• UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 claims 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims 1
• ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 claims 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 claims 1
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
• XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 claims 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 claims 1
• 102000035037 5-HT3 receptors Human genes 0.000 claims 1
• 108091005477 5-HT3 receptors Proteins 0.000 claims 1
• IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 claims 1
• XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 1
• WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 1
• KSEYRUGYKHXGFW-UHFFFAOYSA-N 6-methoxy-N-[(1-prop-2-enyl-2-pyrrolidinyl)methyl]-2H-benzotriazole-5-carboxamide Chemical compound COC1=CC2=NNN=C2C=C1C(=O)NCC1CCCN1CC=C KSEYRUGYKHXGFW-UHFFFAOYSA-N 0.000 claims 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
• VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 1
• ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 claims 1
• 206010000830 Acute leukaemia Diseases 0.000 claims 1
• PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims 1
• PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims 1
• 108010024976 Asparaginase Proteins 0.000 claims 1
• 102000015790 Asparaginase Human genes 0.000 claims 1
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
• KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 1
• 108010006654 Bleomycin Proteins 0.000 claims 1
• 102000004506 Blood Proteins Human genes 0.000 claims 1
• 108010017384 Blood Proteins Proteins 0.000 claims 1
• 206010005949 Bone cancer Diseases 0.000 claims 1
• 208000018084 Bone neoplasm Diseases 0.000 claims 1
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims 1
• 241000283690 Bos taurus Species 0.000 claims 1
• 206010006143 Brain stem glioma Diseases 0.000 claims 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 1
• 101150071146 COX2 gene Proteins 0.000 claims 1
• FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 claims 1
• 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 claims 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
• 241000282472 Canis lupus familiaris Species 0.000 claims 1
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
• 241000283707 Capra Species 0.000 claims 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
• SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 claims 1
• 208000009458 Carcinoma in Situ Diseases 0.000 claims 1
• 208000017897 Carcinoma of esophagus Diseases 0.000 claims 1
• 201000000274 Carcinosarcoma Diseases 0.000 claims 1
• 208000024172 Cardiovascular disease Diseases 0.000 claims 1
• AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 claims 1
• 102000000844 Cell Surface Receptors Human genes 0.000 claims 1
• 108010001857 Cell Surface Receptors Proteins 0.000 claims 1
• 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
• JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 claims 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 1
• 229920002261 Corn starch Polymers 0.000 claims 1
• ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 claims 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
• 108090000695 Cytokines Proteins 0.000 claims 1
• 102000004127 Cytokines Human genes 0.000 claims 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims 1
• 230000005778 DNA damage Effects 0.000 claims 1
• 231100000277 DNA damage Toxicity 0.000 claims 1
• NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 claims 1
• VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 claims 1
• IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 claims 1
• 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 claims 1
• 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 claims 1
• 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 claims 1
• 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 claims 1
• 101150029707 ERBB2 gene Proteins 0.000 claims 1
• XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 claims 1
• SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 claims 1
• 206010014967 Ependymoma Diseases 0.000 claims 1
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
• 241000283086 Equidae Species 0.000 claims 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
• 102100038595 Estrogen receptor Human genes 0.000 claims 1
• 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 1
• 241000272186 Falco columbarius Species 0.000 claims 1
• 241000282326 Felis catus Species 0.000 claims 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
• 102100037813 Focal adhesion kinase 1 Human genes 0.000 claims 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
• 102100039788 GTPase NRas Human genes 0.000 claims 1
• 108010010803 Gelatin Proteins 0.000 claims 1
• 208000032612 Glial tumor Diseases 0.000 claims 1
• 206010018338 Glioma Diseases 0.000 claims 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
• 108010068370 Glutens Proteins 0.000 claims 1
• 208000017604 Hodgkin disease Diseases 0.000 claims 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
• 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims 1
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 claims 1
• 102000008100 Human Serum Albumin Human genes 0.000 claims 1
• 108091006905 Human Serum Albumin Proteins 0.000 claims 1
• VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 1
• STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims 1
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
• 206010061218 Inflammation Diseases 0.000 claims 1
• 102000014150 Interferons Human genes 0.000 claims 1
• 108010050904 Interferons Proteins 0.000 claims 1
• 206010061252 Intraocular melanoma Diseases 0.000 claims 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
• 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
• 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
• 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 1
• 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
• 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
• 239000005536 L01XE08 - Nilotinib Substances 0.000 claims 1
• 239000002118 L01XE12 - Vandetanib Substances 0.000 claims 1
• 239000002145 L01XE14 - Bosutinib Substances 0.000 claims 1
• UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 claims 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
• 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
• 230000037364 MAPK/ERK pathway Effects 0.000 claims 1
• 241000282567 Macaca fascicularis Species 0.000 claims 1
• 241000282560 Macaca mulatta Species 0.000 claims 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims 1
• XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims 1
• XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 claims 1
• 206010027476 Metastases Diseases 0.000 claims 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims 1
• VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 claims 1
• 229930192392 Mitomycin Natural products 0.000 claims 1
• 101100015391 Mus musculus Ralgds gene Proteins 0.000 claims 1
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
• STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims 1
• OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
• LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 claims 1
• 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims 1
• 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
• 208000009905 Neurofibromatoses Diseases 0.000 claims 1
• 208000003019 Neurofibromatosis 1 Diseases 0.000 claims 1
• 108700026224 Neurofibromatosis 2 Genes Proteins 0.000 claims 1
• 208000024834 Neurofibromatosis type 1 Diseases 0.000 claims 1
• 108010085839 Neurofibromin 2 Proteins 0.000 claims 1
• 102000007517 Neurofibromin 2 Human genes 0.000 claims 1
• 208000005890 Neuroma Diseases 0.000 claims 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
• MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 claims 1
• 208000008589 Obesity Diseases 0.000 claims 1
• FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 claims 1
• BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 1
• 101150000187 PTGS2 gene Proteins 0.000 claims 1
• 229930012538 Paclitaxel Natural products 0.000 claims 1
• 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 1
• 235000019483 Peanut oil Nutrition 0.000 claims 1
• 241001494479 Pecora Species 0.000 claims 1
• 208000002471 Penile Neoplasms Diseases 0.000 claims 1
• 108091000080 Phosphotransferase Proteins 0.000 claims 1
• KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 claims 1
• 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
• 201000005746 Pituitary adenoma Diseases 0.000 claims 1
• 206010061538 Pituitary tumour benign Diseases 0.000 claims 1
• 206010035603 Pleural mesothelioma Diseases 0.000 claims 1
• 208000037062 Polyps Diseases 0.000 claims 1
• HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 claims 1
• 241000288906 Primates Species 0.000 claims 1
• 206010036790 Productive cough Diseases 0.000 claims 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
• 206010060862 Prostate cancer Diseases 0.000 claims 1
• 102000007327 Protamines Human genes 0.000 claims 1
• 108010007568 Protamines Proteins 0.000 claims 1
• AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 claims 1
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
• 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
• 206010038389 Renal cancer Diseases 0.000 claims 1
• 201000000582 Retinoblastoma Diseases 0.000 claims 1
• 241000283984 Rodentia Species 0.000 claims 1
• 208000006938 Schwannomatosis Diseases 0.000 claims 1
• 201000010208 Seminoma Diseases 0.000 claims 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 claims 1
• 229920001800 Shellac Polymers 0.000 claims 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
• 208000000453 Skin Neoplasms Diseases 0.000 claims 1
• 206010068771 Soft tissue neoplasm Diseases 0.000 claims 1
• 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
• 231100000632 Spindle poison Toxicity 0.000 claims 1
• 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 claims 1
• 229920002472 Starch Polymers 0.000 claims 1
• 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
• 241000282887 Suidae Species 0.000 claims 1
• 208000000389 T-cell leukemia Diseases 0.000 claims 1
• 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
• NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
• WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 claims 1
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 1
• 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 claims 1
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
• 239000004473 Threonine Substances 0.000 claims 1
• 208000033781 Thyroid carcinoma Diseases 0.000 claims 1
• IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 claims 1
• YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 claims 1
• UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 claims 1
• 208000023915 Ureteral Neoplasms Diseases 0.000 claims 1
• 206010046458 Urethral neoplasms Diseases 0.000 claims 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
• 201000003761 Vaginal carcinoma Diseases 0.000 claims 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
• 208000008383 Wilms tumor Diseases 0.000 claims 1
• 230000003187 abdominal effect Effects 0.000 claims 1
• 150000001242 acetic acid derivatives Chemical class 0.000 claims 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
• USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 claims 1
• 229960004176 aclarubicin Drugs 0.000 claims 1
• 229930183665 actinomycin Natural products 0.000 claims 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 1
• 208000002517 adenoid cystic carcinoma Diseases 0.000 claims 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 claims 1
• 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
• 229960002833 aflibercept Drugs 0.000 claims 1
• 108010081667 aflibercept Proteins 0.000 claims 1
• 230000032683 aging Effects 0.000 claims 1
• 239000000556 agonist Substances 0.000 claims 1
• 229960002478 aldosterone Drugs 0.000 claims 1
• 229960000548 alemtuzumab Drugs 0.000 claims 1
• 229940072056 alginate Drugs 0.000 claims 1
• 235000010443 alginic acid Nutrition 0.000 claims 1
• 229920000615 alginic acid Polymers 0.000 claims 1
• 229960003687 alizapride Drugs 0.000 claims 1
• 239000003513 alkali Substances 0.000 claims 1
• 229910052783 alkali metal Inorganic materials 0.000 claims 1
• 150000001340 alkali metals Chemical class 0.000 claims 1
• 150000001342 alkaline earth metals Chemical class 0.000 claims 1
• 150000008055 alkyl aryl sulfonates Chemical class 0.000 claims 1
• 125000000217 alkyl group Chemical group 0.000 claims 1
• 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 claims 1
• 229940100198 alkylating agent Drugs 0.000 claims 1
• 239000002168 alkylating agent Substances 0.000 claims 1
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 1
• 238000007844 allele-specific PCR Methods 0.000 claims 1
• 208000026935 allergic disease Diseases 0.000 claims 1
• 230000000735 allogeneic effect Effects 0.000 claims 1
• 229940014175 aloxi Drugs 0.000 claims 1
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
• 229960000473 altretamine Drugs 0.000 claims 1
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
• CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 claims 1
• 229940063655 aluminum stearate Drugs 0.000 claims 1
• 229950010817 alvocidib Drugs 0.000 claims 1
• BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 claims 1
• 229940024606 amino acid Drugs 0.000 claims 1
• 125000003277 amino group Chemical group 0.000 claims 1
• 229960002749 aminolevulinic acid Drugs 0.000 claims 1
• 229960003896 aminopterin Drugs 0.000 claims 1
• 210000004381 amniotic fluid Anatomy 0.000 claims 1
• 229960002550 amrubicin Drugs 0.000 claims 1
• VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 claims 1
• 229960001220 amsacrine Drugs 0.000 claims 1
• XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims 1
• 229960001694 anagrelide Drugs 0.000 claims 1
• OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 claims 1
• 229940035676 analgesics Drugs 0.000 claims 1
• 238000004458 analytical method Methods 0.000 claims 1
• 230000003527 anti-angiogenesis Effects 0.000 claims 1
• 230000001093 anti-cancer Effects 0.000 claims 1
• 230000000340 anti-metabolite Effects 0.000 claims 1
• 230000001028 anti-proliverative effect Effects 0.000 claims 1
• 230000000259 anti-tumor effect Effects 0.000 claims 1
• 238000009175 antibody therapy Methods 0.000 claims 1
• 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims 1
• 229940125715 antihistaminic agent Drugs 0.000 claims 1
• 239000000739 antihistaminic agent Substances 0.000 claims 1
• 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 claims 1
• 229940100197 antimetabolite Drugs 0.000 claims 1
• 239000002256 antimetabolite Substances 0.000 claims 1
• 239000002246 antineoplastic agent Substances 0.000 claims 1
• 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 claims 1
• 229940071731 antivert Drugs 0.000 claims 1
• 229940059707 anzemet Drugs 0.000 claims 1
• ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 claims 1
• 229960001372 aprepitant Drugs 0.000 claims 1
• 239000007900 aqueous suspension Substances 0.000 claims 1
• GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims 1
• 229960002594 arsenic trioxide Drugs 0.000 claims 1
• 229940072107 ascorbate Drugs 0.000 claims 1
• 235000010323 ascorbic acid Nutrition 0.000 claims 1
• 239000011668 ascorbic acid Substances 0.000 claims 1
• 229960003272 asparaginase Drugs 0.000 claims 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims 1
• 229940009098 aspartate Drugs 0.000 claims 1
• MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 claims 1
• 229950010993 atrasentan Drugs 0.000 claims 1
• 229960003005 axitinib Drugs 0.000 claims 1
• RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 1
• KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 claims 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
• 150000001541 aziridines Chemical class 0.000 claims 1
• 208000010572 basal-like breast carcinoma Diseases 0.000 claims 1
• 229960004495 beclometasone Drugs 0.000 claims 1
• LNHWXBUNXOXMRL-VWLOTQADSA-N belotecan Chemical compound C1=CC=C2C(CCNC(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 LNHWXBUNXOXMRL-VWLOTQADSA-N 0.000 claims 1
• 229950011276 belotecan Drugs 0.000 claims 1
• 229940088007 benadryl Drugs 0.000 claims 1
• 230000009286 beneficial effect Effects 0.000 claims 1
• 229940077388 benzenesulfonate Drugs 0.000 claims 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 1
• 229940050390 benzoate Drugs 0.000 claims 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims 1
• 229960002537 betamethasone Drugs 0.000 claims 1
• UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 1
• 229960000397 bevacizumab Drugs 0.000 claims 1
• 229960002938 bexarotene Drugs 0.000 claims 1
• 230000008512 biological response Effects 0.000 claims 1
• 230000002051 biphasic effect Effects 0.000 claims 1
• 206010005084 bladder transitional cell carcinoma Diseases 0.000 claims 1
• 201000001528 bladder urothelial carcinoma Diseases 0.000 claims 1
• 229960001561 bleomycin Drugs 0.000 claims 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
• 230000023555 blood coagulation Effects 0.000 claims 1
• 210000004204 blood vessel Anatomy 0.000 claims 1
• 230000037396 body weight Effects 0.000 claims 1
• 210000000988 bone and bone Anatomy 0.000 claims 1
• 210000001185 bone marrow Anatomy 0.000 claims 1
• 229940094219 bonine Drugs 0.000 claims 1
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
• 229960001467 bortezomib Drugs 0.000 claims 1
• 229960003736 bosutinib Drugs 0.000 claims 1
• UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims 1
• 238000002725 brachytherapy Methods 0.000 claims 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
• 229910052794 bromium Inorganic materials 0.000 claims 1
• RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 1
• 229960001736 buprenorphine Drugs 0.000 claims 1
• 229960002092 busulfan Drugs 0.000 claims 1
• 229910052792 caesium Inorganic materials 0.000 claims 1
• TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 claims 1
• 229910052791 calcium Inorganic materials 0.000 claims 1
• 239000011575 calcium Substances 0.000 claims 1
• FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 claims 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 claims 1
• 238000002619 cancer immunotherapy Methods 0.000 claims 1
• 208000035269 cancer or benign tumor Diseases 0.000 claims 1
• 229960004117 capecitabine Drugs 0.000 claims 1
• 229910052799 carbon Inorganic materials 0.000 claims 1
• 229960004562 carboplatin Drugs 0.000 claims 1
• 229960002115 carboquone Drugs 0.000 claims 1
• 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
• 150000007942 carboxylates Chemical class 0.000 claims 1
• 208000011892 carcinosarcoma of the corpus uteri Diseases 0.000 claims 1
• 229960003261 carmofur Drugs 0.000 claims 1
• 229960005243 carmustine Drugs 0.000 claims 1
• 229960002412 cediranib Drugs 0.000 claims 1
• 229960000590 celecoxib Drugs 0.000 claims 1
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
• 239000013592 cell lysate Substances 0.000 claims 1
• 239000001913 cellulose Substances 0.000 claims 1
• 229920002678 cellulose Polymers 0.000 claims 1
• 235000010980 cellulose Nutrition 0.000 claims 1
• YMNCVRSYJBNGLD-KURKYZTESA-N cephalotaxine Chemical compound C([C@@]12C=C([C@H]([C@H]2C2=C3)O)OC)CCN1CCC2=CC1=C3OCO1 YMNCVRSYJBNGLD-KURKYZTESA-N 0.000 claims 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
• 208000019065 cervical carcinoma Diseases 0.000 claims 1
• 201000006612 cervical squamous cell carcinoma Diseases 0.000 claims 1
• 210000003679 cervix uteri Anatomy 0.000 claims 1
• 230000008859 change Effects 0.000 claims 1
• QTFFGPOXNNGTGZ-LIFGOUTFSA-N chembl2368924 Chemical compound O.CS(O)(=O)=O.C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 QTFFGPOXNNGTGZ-LIFGOUTFSA-N 0.000 claims 1
• UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 claims 1
• 238000006243 chemical reaction Methods 0.000 claims 1
• 229940044683 chemotherapy drug Drugs 0.000 claims 1
• 229960004630 chlorambucil Drugs 0.000 claims 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
• ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims 1
• 229960001076 chlorpromazine Drugs 0.000 claims 1
• 239000000812 cholinergic antagonist Substances 0.000 claims 1
• 210000000349 chromosome Anatomy 0.000 claims 1
• 230000001684 chronic effect Effects 0.000 claims 1
• 208000024207 chronic leukemia Diseases 0.000 claims 1
• 229960004316 cisplatin Drugs 0.000 claims 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
• 229960002436 cladribine Drugs 0.000 claims 1
• 229960000928 clofarabine Drugs 0.000 claims 1
• WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 claims 1
• 238000010367 cloning Methods 0.000 claims 1
• 229910017052 cobalt Inorganic materials 0.000 claims 1
• 239000010941 cobalt Substances 0.000 claims 1
• GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims 1
• 229960004126 codeine Drugs 0.000 claims 1
• 239000008119 colloidal silica Substances 0.000 claims 1
• 208000029742 colonic neoplasm Diseases 0.000 claims 1
• 239000003086 colorant Substances 0.000 claims 1
• 229940088505 compazine Drugs 0.000 claims 1
• 229940125846 compound 25 Drugs 0.000 claims 1
• 238000007906 compression Methods 0.000 claims 1
• 230000006835 compression Effects 0.000 claims 1
• 230000037011 constitutive activity Effects 0.000 claims 1
• 230000030944 contact inhibition Effects 0.000 claims 1
• 239000008120 corn starch Substances 0.000 claims 1
• 229960003290 cortisone acetate Drugs 0.000 claims 1
• 229950006799 crisantaspase Drugs 0.000 claims 1
• 210000004748 cultured cell Anatomy 0.000 claims 1
• 238000013211 curve analysis Methods 0.000 claims 1
• 229960003564 cyclizine Drugs 0.000 claims 1
• UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 claims 1
• 229960004397 cyclophosphamide Drugs 0.000 claims 1
• 229960000684 cytarabine Drugs 0.000 claims 1
• 239000000824 cytostatic agent Substances 0.000 claims 1
• 230000001085 cytostatic effect Effects 0.000 claims 1
• 231100000433 cytotoxic Toxicity 0.000 claims 1
• 230000001472 cytotoxic effect Effects 0.000 claims 1
• 229960003901 dacarbazine Drugs 0.000 claims 1
• 229960000640 dactinomycin Drugs 0.000 claims 1
• 229960003603 decitabine Drugs 0.000 claims 1
• 230000003247 decreasing effect Effects 0.000 claims 1
• 238000012217 deletion Methods 0.000 claims 1
• 230000037430 deletion Effects 0.000 claims 1
• 229960005052 demecolcine Drugs 0.000 claims 1
• 229960002923 denileukin diftitox Drugs 0.000 claims 1
• 108010017271 denileukin diftitox Proteins 0.000 claims 1
• 230000002074 deregulated effect Effects 0.000 claims 1
• 229960004486 desoxycorticosterone acetate Drugs 0.000 claims 1
• 239000008121 dextrose Substances 0.000 claims 1
• 206010012601 diabetes mellitus Diseases 0.000 claims 1
• 235000005911 diet Nutrition 0.000 claims 1
• 230000037213 diet Effects 0.000 claims 1
• 235000014113 dietary fatty acids Nutrition 0.000 claims 1
• XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 1
• GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 claims 1
• 229960004993 dimenhydrinate Drugs 0.000 claims 1
• 229960000520 diphenhydramine Drugs 0.000 claims 1
• ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims 1
• 229910000396 dipotassium phosphate Inorganic materials 0.000 claims 1
• 235000019797 dipotassium phosphate Nutrition 0.000 claims 1
• 239000007884 disintegrant Substances 0.000 claims 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 1
• 229960003668 docetaxel Drugs 0.000 claims 1
• POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims 1
• 229960003413 dolasetron Drugs 0.000 claims 1
• 229960001253 domperidone Drugs 0.000 claims 1
• FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 claims 1
• 239000003210 dopamine receptor blocking agent Substances 0.000 claims 1
• 229940099182 dramamine Drugs 0.000 claims 1
• RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 claims 1
• 229960000394 droperidol Drugs 0.000 claims 1
• 239000000890 drug combination Substances 0.000 claims 1
• 229960001776 edrecolomab Drugs 0.000 claims 1
• 229960000925 efaproxiral Drugs 0.000 claims 1
• BNFRJXLZYUTIII-UHFFFAOYSA-N efaproxiral Chemical compound CC1=CC(C)=CC(NC(=O)CC=2C=CC(OC(C)(C)C(O)=O)=CC=2)=C1 BNFRJXLZYUTIII-UHFFFAOYSA-N 0.000 claims 1
• 239000003792 electrolyte Substances 0.000 claims 1
• 229950003247 elesclomol Drugs 0.000 claims 1
• BKJIXTWSNXCKJH-UHFFFAOYSA-N elesclomol Chemical compound C=1C=CC=CC=1C(=S)N(C)NC(=O)CC(=O)NN(C)C(=S)C1=CC=CC=C1 BKJIXTWSNXCKJH-UHFFFAOYSA-N 0.000 claims 1
• 229950002339 elsamitrucin Drugs 0.000 claims 1
• MGQRRMONVLMKJL-KWJIQSIXSA-N elsamitrucin Chemical compound O1[C@H](C)[C@H](O)[C@H](OC)[C@@H](N)[C@H]1O[C@@H]1[C@](O)(C)[C@@H](O)[C@@H](C)O[C@H]1OC1=CC=CC2=C(O)C(C(O3)=O)=C4C5=C3C=CC(C)=C5C(=O)OC4=C12 MGQRRMONVLMKJL-KWJIQSIXSA-N 0.000 claims 1
• 229940108890 emend Drugs 0.000 claims 1
• 239000000839 emulsion Substances 0.000 claims 1
• 201000003683 endocervical adenocarcinoma Diseases 0.000 claims 1
• 230000002124 endocrine Effects 0.000 claims 1
• 210000000750 endocrine system Anatomy 0.000 claims 1
• 229950011487 enocitabine Drugs 0.000 claims 1
• 239000002702 enteric coating Substances 0.000 claims 1
• 238000009505 enteric coating Methods 0.000 claims 1
• 230000002255 enzymatic effect Effects 0.000 claims 1
• 208000023437 ependymal tumor Diseases 0.000 claims 1
• 229960001904 epirubicin Drugs 0.000 claims 1
• 230000007705 epithelial mesenchymal transition Effects 0.000 claims 1
• HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 claims 1
• 229960001842 estramustine Drugs 0.000 claims 1
• FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims 1
• 229940011871 estrogen Drugs 0.000 claims 1
• 239000000262 estrogen Substances 0.000 claims 1
• 108010038795 estrogen receptors Proteins 0.000 claims 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims 1
• 229960005237 etoglucid Drugs 0.000 claims 1
• 229960005420 etoposide Drugs 0.000 claims 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
• 238000011156 evaluation Methods 0.000 claims 1
• 238000007387 excisional biopsy Methods 0.000 claims 1
• 230000007717 exclusion Effects 0.000 claims 1
• 230000029142 excretion Effects 0.000 claims 1
• 238000002710 external beam radiation therapy Methods 0.000 claims 1
• 210000002744 extracellular matrix Anatomy 0.000 claims 1
• 210000001508 eye Anatomy 0.000 claims 1
• 201000001343 fallopian tube carcinoma Diseases 0.000 claims 1
• 239000000194 fatty acid Substances 0.000 claims 1
• 229930195729 fatty acid Natural products 0.000 claims 1
• 150000004665 fatty acids Chemical class 0.000 claims 1
• 239000000796 flavoring agent Substances 0.000 claims 1
• 229960000961 floxuridine Drugs 0.000 claims 1
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims 1
• 229960000390 fludarabine Drugs 0.000 claims 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
• SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 claims 1
• 239000012530 fluid Substances 0.000 claims 1
• 229910052731 fluorine Inorganic materials 0.000 claims 1
• 239000011737 fluorine Substances 0.000 claims 1
• 229960003336 fluorocortisol acetate Drugs 0.000 claims 1
• 229960002949 fluorouracil Drugs 0.000 claims 1
• 238000011010 flushing procedure Methods 0.000 claims 1
• 239000011888 foil Substances 0.000 claims 1
• 235000019152 folic acid Nutrition 0.000 claims 1
• 239000011724 folic acid Substances 0.000 claims 1
• 229960000304 folic acid Drugs 0.000 claims 1
• 235000008191 folinic acid Nutrition 0.000 claims 1
• 239000011672 folinic acid Substances 0.000 claims 1
• VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
• 210000001733 follicular fluid Anatomy 0.000 claims 1
• 229960004783 fotemustine Drugs 0.000 claims 1
• YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 claims 1
• 239000012458 free base Substances 0.000 claims 1
• 108020001507 fusion proteins Proteins 0.000 claims 1
• 102000037865 fusion proteins Human genes 0.000 claims 1
• 210000000232 gallbladder Anatomy 0.000 claims 1
• 230000005251 gamma ray Effects 0.000 claims 1
• 206010017758 gastric cancer Diseases 0.000 claims 1
• 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
• 229960002584 gefitinib Drugs 0.000 claims 1
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
• 229920000159 gelatin Polymers 0.000 claims 1
• 235000019322 gelatine Nutrition 0.000 claims 1
• 235000011852 gelatine desserts Nutrition 0.000 claims 1
• 229960005277 gemcitabine Drugs 0.000 claims 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
• 229960000578 gemtuzumab Drugs 0.000 claims 1
• 230000014509 gene expression Effects 0.000 claims 1
• 229940084910 gliadel Drugs 0.000 claims 1
• 208000005017 glioblastoma Diseases 0.000 claims 1
• 229940050410 gluconate Drugs 0.000 claims 1
• 235000021312 gluten Nutrition 0.000 claims 1
• 125000005456 glyceride group Chemical group 0.000 claims 1
• 229960002449 glycine Drugs 0.000 claims 1
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
• 229960003727 granisetron Drugs 0.000 claims 1
• MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims 1
• 238000000227 grinding Methods 0.000 claims 1
• 230000003394 haemopoietic effect Effects 0.000 claims 1
• 150000004820 halides Chemical class 0.000 claims 1
• 229960003878 haloperidol Drugs 0.000 claims 1
• 230000036541 health Effects 0.000 claims 1
• 230000003862 health status Effects 0.000 claims 1
• 201000005787 hematologic cancer Diseases 0.000 claims 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
• 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims 1
• 229940022353 herceptin Drugs 0.000 claims 1
• IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims 1
• UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 1
• 208000027671 high grade ependymoma Diseases 0.000 claims 1
• 210000003630 histaminocyte Anatomy 0.000 claims 1
• 150000002429 hydrazines Chemical class 0.000 claims 1
• LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 1
• 229960000240 hydrocodone Drugs 0.000 claims 1
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
• 229960001330 hydroxycarbamide Drugs 0.000 claims 1
• 229960000930 hydroxyzine Drugs 0.000 claims 1
• ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims 1
• 230000006607 hypermethylation Effects 0.000 claims 1
• 229960000908 idarubicin Drugs 0.000 claims 1
• 229960001101 ifosfamide Drugs 0.000 claims 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
• 229960002411 imatinib Drugs 0.000 claims 1
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
• 210000002865 immune cell Anatomy 0.000 claims 1
• 210000000987 immune system Anatomy 0.000 claims 1
• 239000007943 implant Substances 0.000 claims 1
• 201000004933 in situ carcinoma Diseases 0.000 claims 1
• 238000007386 incisional biopsy Methods 0.000 claims 1
• 230000002757 inflammatory effect Effects 0.000 claims 1
• 230000004054 inflammatory process Effects 0.000 claims 1
• 229940047124 interferons Drugs 0.000 claims 1
• 206010073096 invasive lobular breast carcinoma Diseases 0.000 claims 1
• PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
• 238000005342 ion exchange Methods 0.000 claims 1
• 150000002500 ions Chemical class 0.000 claims 1
• 229960004768 irinotecan Drugs 0.000 claims 1
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
• 229950005254 irofulven Drugs 0.000 claims 1
• NICJCIQSJJKZAH-AWEZNQCLSA-N irofulven Chemical compound O=C([C@@]1(O)C)C2=CC(C)=C(CO)C2=C(C)C21CC2 NICJCIQSJJKZAH-AWEZNQCLSA-N 0.000 claims 1
• 230000007794 irritation Effects 0.000 claims 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims 1
• 229960002014 ixabepilone Drugs 0.000 claims 1
• FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 claims 1
• 201000010982 kidney cancer Diseases 0.000 claims 1
• 229940043355 kinase inhibitor Drugs 0.000 claims 1
• 238000002372 labelling Methods 0.000 claims 1
• 229940001447 lactate Drugs 0.000 claims 1
• 229940099584 lactobionate Drugs 0.000 claims 1
• JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 claims 1
• 229960004891 lapatinib Drugs 0.000 claims 1
• BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
• 210000002429 large intestine Anatomy 0.000 claims 1
• 229950005692 larotaxel Drugs 0.000 claims 1
• SEFGUGYLLVNFIJ-QDRLFVHASA-N larotaxel dihydrate Chemical compound O.O.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@@]23[C@H]1[C@@]1(CO[C@@H]1C[C@@H]2C3)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 SEFGUGYLLVNFIJ-QDRLFVHASA-N 0.000 claims 1
• 229940070765 laurate Drugs 0.000 claims 1
• 239000000787 lecithin Substances 0.000 claims 1
• 229940067606 lecithin Drugs 0.000 claims 1
• 235000010445 lecithin Nutrition 0.000 claims 1
• 230000003902 lesion Effects 0.000 claims 1
• 229950001845 lestaurtinib Drugs 0.000 claims 1
• 229960001691 leucovorin Drugs 0.000 claims 1
• 229910052744 lithium Inorganic materials 0.000 claims 1
• 201000007270 liver cancer Diseases 0.000 claims 1
• 208000014018 liver neoplasm Diseases 0.000 claims 1
• 229960002247 lomustine Drugs 0.000 claims 1
• 229960003538 lonidamine Drugs 0.000 claims 1
• WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 claims 1
• 229960004391 lorazepam Drugs 0.000 claims 1
• 239000000314 lubricant Substances 0.000 claims 1
• FBQPGGIHOFZRGH-UHFFFAOYSA-N lucanthone Chemical compound S1C2=CC=CC=C2C(=O)C2=C1C(C)=CC=C2NCCN(CC)CC FBQPGGIHOFZRGH-UHFFFAOYSA-N 0.000 claims 1
• 229950005239 lucanthone Drugs 0.000 claims 1
• 210000004880 lymph fluid Anatomy 0.000 claims 1
• 239000006166 lysate Substances 0.000 claims 1
• 229910052749 magnesium Inorganic materials 0.000 claims 1
• 239000011777 magnesium Substances 0.000 claims 1
• 239000000391 magnesium silicate Substances 0.000 claims 1
• 229940099273 magnesium trisilicate Drugs 0.000 claims 1
• 229910000386 magnesium trisilicate Inorganic materials 0.000 claims 1
• 235000019793 magnesium trisilicate Nutrition 0.000 claims 1
• 229940049920 malate Drugs 0.000 claims 1
• 239000011976 maleic acid Substances 0.000 claims 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
• 208000026037 malignant tumor of neck Diseases 0.000 claims 1
• UUVIQYKKKBJYJT-ZYUZMQFOSA-N mannosulfan Chemical compound CS(=O)(=O)OC[C@@H](OS(C)(=O)=O)[C@@H](O)[C@H](O)[C@H](OS(C)(=O)=O)COS(C)(=O)=O UUVIQYKKKBJYJT-ZYUZMQFOSA-N 0.000 claims 1
• 229960000733 mannosulfan Drugs 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 229960003951 masoprocol Drugs 0.000 claims 1
• HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 claims 1
• 238000005259 measurement Methods 0.000 claims 1
• 229960004961 mechlorethamine Drugs 0.000 claims 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 1
• 229960001474 meclozine Drugs 0.000 claims 1
• 239000002609 medium Substances 0.000 claims 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
• 229960001924 melphalan Drugs 0.000 claims 1
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 1
• 229960001428 mercaptopurine Drugs 0.000 claims 1
• 229960004635 mesna Drugs 0.000 claims 1
• 229910052751 metal Inorganic materials 0.000 claims 1
• 239000002184 metal Substances 0.000 claims 1
• 208000037819 metastatic cancer Diseases 0.000 claims 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
• 229960000485 methotrexate Drugs 0.000 claims 1
• YUUAYBAIHCDHHD-UHFFFAOYSA-N methyl 5-aminolevulinate Chemical compound COC(=O)CCC(=O)CN YUUAYBAIHCDHHD-UHFFFAOYSA-N 0.000 claims 1
• 229960005033 methyl aminolevulinate Drugs 0.000 claims 1
• 229960004584 methylprednisolone Drugs 0.000 claims 1
• 229960004503 metoclopramide Drugs 0.000 claims 1
• 229960003793 midazolam Drugs 0.000 claims 1
• DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 claims 1
• 235000013336 milk Nutrition 0.000 claims 1
• 239000008267 milk Substances 0.000 claims 1
• 210000004080 milk Anatomy 0.000 claims 1
• 229960001785 mirtazapine Drugs 0.000 claims 1
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims 1
• 229960005485 mitobronitol Drugs 0.000 claims 1
• 229960003539 mitoguazone Drugs 0.000 claims 1
• MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 claims 1
• 229960004857 mitomycin Drugs 0.000 claims 1
• 229960000350 mitotane Drugs 0.000 claims 1
• 229960001156 mitoxantrone Drugs 0.000 claims 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
• 230000004048 modification Effects 0.000 claims 1
• 238000012986 modification Methods 0.000 claims 1
• 238000002625 monoclonal antibody therapy Methods 0.000 claims 1
• 229960005181 morphine Drugs 0.000 claims 1
• 210000003097 mucus Anatomy 0.000 claims 1
• 210000003205 muscle Anatomy 0.000 claims 1
• 230000000869 mutational effect Effects 0.000 claims 1
• RCHQNUQAHJNRBY-UHFFFAOYSA-N n-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide;hydrochloride Chemical compound Cl.C1=CC(C(=O)NC)=CC=C1NC1=NC=C(C(F)(F)F)C(NCC=2C(=NC=CN=2)N(C)S(C)(=O)=O)=N1 RCHQNUQAHJNRBY-UHFFFAOYSA-N 0.000 claims 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 claims 1
• 201000011216 nasopharynx carcinoma Diseases 0.000 claims 1
• 229950007221 nedaplatin Drugs 0.000 claims 1
• 238000013188 needle biopsy Methods 0.000 claims 1
• 206010061311 nervous system neoplasm Diseases 0.000 claims 1
• 208000007538 neurilemmoma Diseases 0.000 claims 1
• 201000009494 neurilemmomatosis Diseases 0.000 claims 1
• 230000000626 neurodegenerative effect Effects 0.000 claims 1
• 201000004931 neurofibromatosis Diseases 0.000 claims 1
• 208000002761 neurofibromatosis 2 Diseases 0.000 claims 1
• 208000022032 neurofibromatosis type 2 Diseases 0.000 claims 1
• 235000001968 nicotinic acid Nutrition 0.000 claims 1
• 239000011664 nicotinic acid Substances 0.000 claims 1
• 229960001346 nilotinib Drugs 0.000 claims 1
• HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 1
• 229960001420 nimustine Drugs 0.000 claims 1
• VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 claims 1
• 229910052757 nitrogen Inorganic materials 0.000 claims 1
• 239000012457 nonaqueous media Substances 0.000 claims 1
• 239000002773 nucleotide Substances 0.000 claims 1
• 125000003729 nucleotide group Chemical group 0.000 claims 1
• 235000020824 obesity Nutrition 0.000 claims 1
• 229960000435 oblimersen Drugs 0.000 claims 1
• MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 claims 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
• 201000002575 ocular melanoma Diseases 0.000 claims 1
• 239000003921 oil Substances 0.000 claims 1
• 235000019198 oils Nutrition 0.000 claims 1
• KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 1
• 229960005017 olanzapine Drugs 0.000 claims 1
• 229940049964 oleate Drugs 0.000 claims 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
• 229940005619 omacetaxine Drugs 0.000 claims 1
• 238000011275 oncology therapy Methods 0.000 claims 1
• 239000003605 opacifier Substances 0.000 claims 1
• 229940127240 opiate Drugs 0.000 claims 1
• 210000000056 organ Anatomy 0.000 claims 1
• 210000004789 organ system Anatomy 0.000 claims 1
• 229950001094 ortataxel Drugs 0.000 claims 1
• BWKDAMBGCPRVPI-ZQRPHVBESA-N ortataxel Chemical compound O([C@@H]1[C@]23OC(=O)O[C@H]2[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]2(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]21)OC(C)=O)C3(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 BWKDAMBGCPRVPI-ZQRPHVBESA-N 0.000 claims 1
• 201000008968 osteosarcoma Diseases 0.000 claims 1
• 230000002018 overexpression Effects 0.000 claims 1
• 235000006408 oxalic acid Nutrition 0.000 claims 1
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
• 229960001756 oxaliplatin Drugs 0.000 claims 1
• 229960002085 oxycodone Drugs 0.000 claims 1
• 229960001592 paclitaxel Drugs 0.000 claims 1
• 229960002131 palonosetron Drugs 0.000 claims 1
• 210000000496 pancreas Anatomy 0.000 claims 1
• 229960001972 panitumumab Drugs 0.000 claims 1
• 210000002990 parathyroid gland Anatomy 0.000 claims 1
• 238000002727 particle therapy Methods 0.000 claims 1
• 239000000312 peanut oil Substances 0.000 claims 1
• 229960001744 pegaspargase Drugs 0.000 claims 1
• 108010001564 pegaspargase Proteins 0.000 claims 1
• 229960005079 pemetrexed Drugs 0.000 claims 1
• QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 1
• ALAGDBVXZZADSN-UHFFFAOYSA-N pentazine Chemical compound C1=NN=NN=N1 ALAGDBVXZZADSN-UHFFFAOYSA-N 0.000 claims 1
• 229960002340 pentostatin Drugs 0.000 claims 1
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims 1
• 230000000737 periodic effect Effects 0.000 claims 1
• 229940083251 peripheral vasodilators purine derivative Drugs 0.000 claims 1
• JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 claims 1
• 229960000482 pethidine Drugs 0.000 claims 1
• 239000003208 petroleum Substances 0.000 claims 1
• 239000008177 pharmaceutical agent Substances 0.000 claims 1
• 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
• 229940107333 phenergan Drugs 0.000 claims 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
• 102000020233 phosphotransferase Human genes 0.000 claims 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
• 229940075930 picrate Drugs 0.000 claims 1
• OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 claims 1
• 229960001221 pirarubicin Drugs 0.000 claims 1
• 208000021310 pituitary gland adenoma Diseases 0.000 claims 1
• 229950010765 pivalate Drugs 0.000 claims 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 claims 1
• 239000004033 plastic Substances 0.000 claims 1
• 229920003023 plastic Polymers 0.000 claims 1
• 239000004014 plasticizer Substances 0.000 claims 1
• 229910052697 platinum Inorganic materials 0.000 claims 1
• 229960003171 plicamycin Drugs 0.000 claims 1
• 229920000058 polyacrylate Polymers 0.000 claims 1
• 229920000642 polymer Polymers 0.000 claims 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
• 229960004293 porfimer sodium Drugs 0.000 claims 1
• 230000002980 postoperative effect Effects 0.000 claims 1
• XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
• 235000010241 potassium sorbate Nutrition 0.000 claims 1
• 239000004302 potassium sorbate Substances 0.000 claims 1
• 229940069338 potassium sorbate Drugs 0.000 claims 1
• 230000003389 potentiating effect Effects 0.000 claims 1
• 229960004694 prednimustine Drugs 0.000 claims 1
• 229960005205 prednisolone Drugs 0.000 claims 1
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
• 229960004618 prednisone Drugs 0.000 claims 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
• 239000000955 prescription drug Substances 0.000 claims 1
• 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
• 229960000624 procarbazine Drugs 0.000 claims 1
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims 1
• 239000000583 progesterone congener Substances 0.000 claims 1
• 102000003998 progesterone receptors Human genes 0.000 claims 1
• 108090000468 progesterone receptors Proteins 0.000 claims 1
• 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 claims 1
• 230000035755 proliferation Effects 0.000 claims 1
• 235000019260 propionic acid Nutrition 0.000 claims 1
• 150000005599 propionic acid derivatives Chemical class 0.000 claims 1
• 229940048914 protamine Drugs 0.000 claims 1
• 230000004853 protein function Effects 0.000 claims 1
• 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 claims 1
• 238000012175 pyrosequencing Methods 0.000 claims 1
• 125000001453 quaternary ammonium group Chemical group 0.000 claims 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
• 230000002285 radioactive effect Effects 0.000 claims 1
• 229960004432 raltitrexed Drugs 0.000 claims 1
• 229960002185 ranimustine Drugs 0.000 claims 1
• 238000003753 real-time PCR Methods 0.000 claims 1
• 206010038038 rectal cancer Diseases 0.000 claims 1
• 210000000664 rectum Anatomy 0.000 claims 1
• 201000001275 rectum cancer Diseases 0.000 claims 1
• 230000000306 recurrent effect Effects 0.000 claims 1
• 229940080693 reglan Drugs 0.000 claims 1
• 230000001105 regulatory effect Effects 0.000 claims 1
• 230000008844 regulatory mechanism Effects 0.000 claims 1
• 229940023942 remeron Drugs 0.000 claims 1
• 201000007444 renal pelvis carcinoma Diseases 0.000 claims 1
• 230000008439 repair process Effects 0.000 claims 1
• 230000010076 replication Effects 0.000 claims 1
• 230000002207 retinal effect Effects 0.000 claims 1
• 229960004641 rituximab Drugs 0.000 claims 1
• VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 claims 1
• 229950009213 rubitecan Drugs 0.000 claims 1
• 210000003296 saliva Anatomy 0.000 claims 1
• 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 claims 1
• 229940059160 sancuso Drugs 0.000 claims 1
• 229950006896 sapacitabine Drugs 0.000 claims 1
• LBGFKUUHOPIEMA-PEARBKPGSA-N sapacitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](C#N)[C@H](O)[C@@H](CO)O1 LBGFKUUHOPIEMA-PEARBKPGSA-N 0.000 claims 1
• 229920006395 saturated elastomer Polymers 0.000 claims 1
• 206010039667 schwannoma Diseases 0.000 claims 1
• STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims 1
• 229960002646 scopolamine Drugs 0.000 claims 1
• 238000011519 second-line treatment Methods 0.000 claims 1
• 229950000055 seliciclib Drugs 0.000 claims 1
• BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 claims 1
• 229950003647 semaxanib Drugs 0.000 claims 1
• WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 claims 1
• 210000000582 semen Anatomy 0.000 claims 1
• 229960003440 semustine Drugs 0.000 claims 1
• 238000000926 separation method Methods 0.000 claims 1
• 239000008159 sesame oil Substances 0.000 claims 1
• 235000011803 sesame oil Nutrition 0.000 claims 1
• 235000013874 shellac Nutrition 0.000 claims 1
• 229960000269 sitimagene ceradenovec Drugs 0.000 claims 1
• 108010086606 sitimagene ceradenovec Proteins 0.000 claims 1
• 201000000849 skin cancer Diseases 0.000 claims 1
• 239000002002 slurry Substances 0.000 claims 1
• AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims 1
• 229910052708 sodium Inorganic materials 0.000 claims 1
• 239000011734 sodium Substances 0.000 claims 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
• 239000007787 solid Substances 0.000 claims 1
• 239000012439 solid excipient Substances 0.000 claims 1
• 229960003787 sorafenib Drugs 0.000 claims 1
• 235000010199 sorbic acid Nutrition 0.000 claims 1
• 239000004334 sorbic acid Substances 0.000 claims 1
• 229940075582 sorbic acid Drugs 0.000 claims 1
• 210000003802 sputum Anatomy 0.000 claims 1
• 208000024794 sputum Diseases 0.000 claims 1
• 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
• 239000003381 stabilizer Substances 0.000 claims 1
• 238000011301 standard therapy Methods 0.000 claims 1
• 235000019698 starch Nutrition 0.000 claims 1
• 201000011549 stomach cancer Diseases 0.000 claims 1
• 229960001052 streptozocin Drugs 0.000 claims 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims 1
• 230000035882 stress Effects 0.000 claims 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
• 239000001384 succinic acid Substances 0.000 claims 1
• 229960001796 sunitinib Drugs 0.000 claims 1
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
• 208000014794 superficial urinary bladder carcinoma Diseases 0.000 claims 1
• 239000006228 supernatant Substances 0.000 claims 1
• 238000013268 sustained release Methods 0.000 claims 1
• 239000012730 sustained-release form Substances 0.000 claims 1
• 230000002195 synergetic effect Effects 0.000 claims 1
• 210000001179 synovial fluid Anatomy 0.000 claims 1
• 238000002942 systemic radioisotope therapy Methods 0.000 claims 1
• 235000002906 tartaric acid Nutrition 0.000 claims 1
• 239000011975 tartaric acid Substances 0.000 claims 1
• 229940095064 tartrate Drugs 0.000 claims 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
• 210000001138 tear Anatomy 0.000 claims 1
• 229960002197 temoporfin Drugs 0.000 claims 1
• 229960004964 temozolomide Drugs 0.000 claims 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims 1
• 229960001278 teniposide Drugs 0.000 claims 1
• 229950009016 tesetaxel Drugs 0.000 claims 1
• MODVSQKJJIBWPZ-VLLPJHQWSA-N tesetaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3CC[C@@]2(C)[C@H]2[C@@H](C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C(=CC=CN=4)F)C[C@]1(O)C3(C)C)O[C@H](O2)CN(C)C)C(=O)C1=CC=CC=C1 MODVSQKJJIBWPZ-VLLPJHQWSA-N 0.000 claims 1
• 230000002381 testicular Effects 0.000 claims 1
• 238000012360 testing method Methods 0.000 claims 1
• 229960005353 testolactone Drugs 0.000 claims 1
• BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 claims 1
• 229960003604 testosterone Drugs 0.000 claims 1
• 238000011285 therapeutic regimen Methods 0.000 claims 1
• 239000002562 thickening agent Substances 0.000 claims 1
• 229960001196 thiotepa Drugs 0.000 claims 1
• 208000013077 thyroid gland carcinoma Diseases 0.000 claims 1
• 229960003723 tiazofurine Drugs 0.000 claims 1
• FVRDYQYEVDDKCR-DBRKOABJSA-N tiazofurine Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 claims 1
• 229960003087 tioguanine Drugs 0.000 claims 1
• MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims 1
• 229950009158 tipifarnib Drugs 0.000 claims 1
• PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 claims 1
• 239000003104 tissue culture media Substances 0.000 claims 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
• 229960000303 topotecan Drugs 0.000 claims 1
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
• 230000001988 toxicity Effects 0.000 claims 1
• 231100000419 toxicity Toxicity 0.000 claims 1
• 229960000977 trabectedin Drugs 0.000 claims 1
• PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 claims 1
• 229960004380 tramadol Drugs 0.000 claims 1
• TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 1
• OQUFJVRYDFIQBW-UHFFFAOYSA-N trametinib dimethyl sulfoxide Chemical compound CS(C)=O.CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 OQUFJVRYDFIQBW-UHFFFAOYSA-N 0.000 claims 1
• LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims 1
• 238000011269 treatment regimen Methods 0.000 claims 1
• 229960003181 treosulfan Drugs 0.000 claims 1
• 229950001353 tretamine Drugs 0.000 claims 1
• IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 claims 1
• 229960001727 tretinoin Drugs 0.000 claims 1
• 229960005294 triamcinolone Drugs 0.000 claims 1
• GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
• 150000004654 triazenes Chemical class 0.000 claims 1
• PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 claims 1
• 229960004560 triaziquone Drugs 0.000 claims 1
• UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 claims 1
• 229960000875 trofosfamide Drugs 0.000 claims 1
• 210000004881 tumor cell Anatomy 0.000 claims 1
• 230000004614 tumor growth Effects 0.000 claims 1
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
• 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
• ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 claims 1
• 238000002628 unsealed source radiotherapy Methods 0.000 claims 1
• 229960001055 uracil mustard Drugs 0.000 claims 1
• 210000000626 ureter Anatomy 0.000 claims 1
• 201000005290 uterine carcinosarcoma Diseases 0.000 claims 1
• 229940070710 valerate Drugs 0.000 claims 1
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 1
• 239000004474 valine Substances 0.000 claims 1
• 229960000653 valrubicin Drugs 0.000 claims 1
• ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 claims 1
• 229960000241 vandetanib Drugs 0.000 claims 1
• UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 1
• PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 1
• 229960004688 venlafaxine Drugs 0.000 claims 1
• 229960003895 verteporfin Drugs 0.000 claims 1
• ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 claims 1
• 229960003048 vinblastine Drugs 0.000 claims 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
• 229960004528 vincristine Drugs 0.000 claims 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
• 229960004355 vindesine Drugs 0.000 claims 1
• UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims 1
• NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 claims 1
• 229960000922 vinflunine Drugs 0.000 claims 1
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 1
• 229960002066 vinorelbine Drugs 0.000 claims 1
• WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 1
• 229960000237 vorinostat Drugs 0.000 claims 1
• 208000013013 vulvar carcinoma Diseases 0.000 claims 1
• 239000001993 wax Substances 0.000 claims 1
• 210000002268 wool Anatomy 0.000 claims 1
• 229920001285 xanthan gum Polymers 0.000 claims 1
• 150000003751 zinc Chemical class 0.000 claims 1
• 229960000641 zorubicin Drugs 0.000 claims 1
• FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 claims 1
• 102000016914 ras Proteins Human genes 0.000 description 4
• 108700020796 Oncogene Proteins 0.000 description 2
• 230000019491 signal transduction Effects 0.000 description 2
• 206010004593 Bile duct cancer Diseases 0.000 description 1
• 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
• 102000043276 Oncogene Human genes 0.000 description 1
• 229940124639 Selective inhibitor Drugs 0.000 description 1
• 102100025093 Zinc fingers and homeoboxes protein 2 Human genes 0.000 description 1
• 208000026900 bile duct neoplasm Diseases 0.000 description 1
• 208000006990 cholangiocarcinoma Diseases 0.000 description 1
• 230000001351 cycling effect Effects 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 201000010175 gallbladder cancer Diseases 0.000 description 1
• 108010014186 ras Proteins Proteins 0.000 description 1
• 102000030938 small GTPase Human genes 0.000 description 1
• 108060007624 small GTPase Proteins 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1